1-20 of 39
Michael J Thirman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

CME Clinical Trials & Observations
Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea
Journal: Blood
Blood (2024) 144 (21): 2211–2222.
https://doi.org/10.1182/blood.2024024944
Published: 2024
Includes: Supplemental data
Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Ibrahim Aldoss, Ghayas C. Issa, Michael J Thirman, John DiPersio, Martha Arellano, James S. Blachly, Gabriel Mannis, Alexander Perl, David Dickens, Christine M. McMahon, Elie Traer, C. Michel Zwaan, Carolyn Grove, Richard Stone, Paul J Shami, Ioannis Mantzaris, Matthew Greenwood, Neerav Shukla, Branko Cuglievan, Yu Gu, Rebecca G Bagley, Kate Madigan, Soujanya Sunkaraneni, Huy Van Nguyen, Nicole McNeer, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 2907.
https://doi.org/10.1182/blood-2023-189762
Published: 2023
Journal Articles

Variable Response of MLL-Rearranged Leukemia Cell Lines to Combinations of Menin, CDK9 and DOT1L Inhibitors

Aysenur Esen, Roger Luo, Joseph Kaberlein, Michael J Thirman
Journal: Blood
Blood (2023) 142 (Supplement 1): 5747.
https://doi.org/10.1182/blood-2023-177700
Published: 2023
Journal Articles

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Alexey Danilov, Michael T. Tees, Krish Patel, William G. Wierda, Manish Patel, Ian W. Flinn, Tahir Latif, Weiyun Ai, Meghan C. Thompson, Michael L. Wang, Clare Sun, Deborah M. Stephens, Michael J Thirman, Melissa Gessner, Johannes Wolff, Amanda Schwab, May Tan, Daniel Chan, Erin Meredith, Adrian Wiestner
Journal: Blood
Blood (2023) 142 (Supplement 1): 4463.
https://doi.org/10.1182/blood-2023-179872
Published: 2023
Journal Articles

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J Thirman, Stanley Kotey, Jalaja Potluri, Mazaher Dhalla, Vinod Pullarkat
Journal: Blood
Blood (2023) 142 (Supplement 1): 2886.
https://doi.org/10.1182/blood-2023-182045
Published: 2023
Journal Articles

Socioeconomic Determinants and the Biology and Outcomes of Acute Lymphoblastic Leukemia in Adults

Hannah Johnston, Hamed Youshanlouei, Clinton Osei, Anand Ashwin Patel, Adam S Duvall, Peng Wang, Pankhuri Wanjari, Jeremy Segal, Girish Venkataraman, Sandeep Gurbuxani, Angela Lager, Carrie Fitzpatrick, Michael J Thirman, Christopher Daugherty, Mariam T. Nawas, Hongtao Liu, Michael Drazer, Olatoyosi Odenike, Richard Larson, Wendy Stock, Caner Saygin
Journal: Blood
Blood (2023) 142 (Supplement 1): 1468.
https://doi.org/10.1182/blood-2023-174963
Published: 2023
Journal Articles

Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers

Emily Symes, Zhihong Hu, Stephen K. Walker, Vishakha Sovani, Nicolas Lopez-Hisijos, Barina Aqil, Mir Alikhan, Claudiu V. Cotta, Sean Harrop, Angela Lager, Beenu Thakral, Peter A. Riedell, Carrie Fitzpatrick, Michael J. Thirman, Anand Ashwin Patel, Caner Saygin, Sandra L. Ondrejka, Michael R. Bishop, Amir Behdad, Sandeep Gurbuxani, Daniel A. Arber, M. James You, Richard A. Larson, Sonali M. Smith, Yan Amber Hodgson, Justin Kline, Matthew Ku, Girish Venkataraman
Journal: Blood
Blood (2022) 140 (Supplement 1): 2053–2055.
https://doi.org/10.1182/blood-2022-155950
Published: 2022
Journal Articles

ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Recher, Andre C. Schuh, Sunil Babu, Monique Dail, Grace Ku, Yan Sun, Jalaja Potluri, Brenda Chyla, Daniel A. Pollyea
Journal: Blood
Blood (2022) 140 (Supplement 1): 1441–1444.
https://doi.org/10.1182/blood-2022-169509
Published: 2022
Journal Articles

Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A. Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S. Garcia, David Rizzieri, Michael J. Thirman, Melissa Montez, Yingyi Liu, John Katsetos, Jalaja Potluri, Catherine Miller, Vinod A. Pullarkat
Journal: Blood
Blood (2022) 140 (Supplement 1): 8993–8995.
https://doi.org/10.1182/blood-2022-158500
Published: 2022
Journal Articles

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience

Ghayas C. Issa, Branko Cuglievan, Eytan Stein, Martha L. Arellano, Andrius Žucenka, Nandita Khera, Richard M. Stone, Michael J. Thirman, John F. DiPersio, Nicole Karras, Yu Gu, Rebecca G. Bagley, Galit Rosen, David Tamang, Kimberly Dishman, Sushama Scalera, Michael L. Meyers, Kate Madigan, Nicole McNeer, Ibrahim Aldoss
Journal: Blood
Blood (2022) 140 (Supplement 1): 914–916.
https://doi.org/10.1182/blood-2022-164600
Published: 2022
Journal Articles

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Keith W. Pratz, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung-Soo Yoon, Ofir Wolach, Jun-Ho Jang, Su-Peng Yeh, Grace Ku, Ying Zhou, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo
Journal: Blood
Blood (2022) 140 (Supplement 1): 529–531.
https://doi.org/10.1182/blood-2022-158518
Published: 2022
Journal Articles

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A -Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio, Branko Cuglievan, Richard M. Stone, Martha L. Arellano, Michael J. Thirman, Manish R. Patel, David Dickens, Shalini Shenoy, Neerav Shukla, Galit Rosen, Rebecca G. Bagley, Michael L. Meyers, Kate Madigan, Peter Ordentlich, Yu Gu, Steven Smith, Gerard M. McGeehan, Eytan Stein
Journal: Blood
Blood (2022) 140 (Supplement 1): 150–152.
https://doi.org/10.1182/blood-2022-164849
Published: 2022
Journal Articles

Epigenetic regulator genes direct lineage switching in  MLL/AF4 leukemia

Ricky Tirtakusuma, Katarzyna Szoltysek, Paul Milne, Vasily V. Grinev, Anetta Ptasinska, Paulynn S. Chin, Claus Meyer, Sirintra Nakjang, Jayne Y. Hehir-Kwa, Daniel Williamson, Pierre Cauchy, Peter Keane, Salam A. Assi, Minoo Ashtiani, Sophie G. Kellaway, Maria R. Imperato, Fotini Vogiatzi, Elizabeth K. Schweighart, Shan Lin, Mark Wunderlich, Janine Stutterheim, Alexander Komkov, Elena Zerkalenkova, Paul Evans, Hesta McNeill, Alex Elder, Natalia Martinez-Soria, Sarah E. Fordham, Yuzhe Shi, Lisa J. Russell, Deepali Pal, Alex Smith, Zoya Kingsbury, Jennifer Becq, Cornelia Eckert, Oskar A. Haas, Peter Carey, Simon Bailey, Roderick Skinner, Natalia Miakova, Matthew Collin, Venetia Bigley, Muzlifah Haniffa, Rolf Marschalek, Christine J. Harrison, Catherine A. Cargo, Denis Schewe, Yulia Olshanskaya, Michael J. Thirman, Peter N. Cockerill, James C. Mulloy, Helen J. Blair, Josef Vormoor, James M. Allan, Constanze Bonifer, Olaf Heidenreich, Simon Bomken
Journal: Blood
Blood (2022) 140 (17): 1875–1890.
https://doi.org/10.1182/blood.2021015036
Published: 2022
Includes: Supplemental data
Journal Articles

The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment

Brief Report
Shan Lin, Roger T. Luo, Mahesh Shrestha, Michael J. Thirman, James C. Mulloy
Journal: Blood
Blood (2017) 130 (7): 903–907.
https://doi.org/10.1182/blood-2017-04-777185
Published: 2017
Includes: Supplemental data
Journal Articles

Clonal Evolution Pattern of Leukemia Progression and Richter Transformation in Ibrutinib-Relapsed CLL Patients

Sabah Kadri, PhD, Jimmy Lee, MD, Carrie Fitzpatrick, PhD DABMG, Natalie Galanina, MD, Madina Sukhanova, PhD, Girish Venkataraman, MD MBBS, Shruti Sharma, PhD, Bradley Long, Megan Theissen, Mei Ming, PhD, Yuri Kobzev, Kang Wenjun, Ailin Guo, PhD MD, Weige V Wang, MD, Nifang Niu, PhD, Howie Lawrence Weiner, Michael J. Thirman, MD, Sonali M. Smith, MD, Jeremy P. Segal, MD PhD, Pin Lu, PhD, Y. Lynn Wang, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3961.
https://doi.org/10.1182/blood.V128.22.3961.3961
Published: 2016
Journal Articles

The Transcriptome Heterogeneity of MLL-Fusion ALL Is Driven By Fusion Partners Via Distinct Chromatin Binding

Shan Lin, Anetta Ptasinska, PhD, Salam Adli Assi, Jon Kerry, Ruhikanta A. Meetei, PhD, Roger T. Luo, PhD, Michael J. Thirman, MD, Thomas Milne, PhD, Constanze Bonifer, PhD, James C. Mulloy, PhD
Journal: Blood
Blood (2016) 128 (22): 576.
https://doi.org/10.1182/blood.V128.22.576.576
Published: 2016
Journal Articles

Combination of Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Is Feasible and Tolerable

Amy Y Wang, MD, Howie Lawrence Weiner, Margaret Green, Richard A. Larson, MD, Olatoyosi Odenike, MD, Andrew Artz, MD, Lucy A Godley, MD, PhD, Michael J. Thirman, MD, Jane E Churpek, MD, Emily K. Curran, MD, Kristen Pettit, MD, Wendy Stock, MD, Hongtao Liu, MDPhD
Journal: Blood
Blood (2016) 128 (22): 212.
https://doi.org/10.1182/blood.V128.22.212.212
Published: 2016
Journal Articles

Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML)

Andrew Hantel, MD, Niloufer Khan, MD, Richard A. Larson, MD, Lucy A. Godley, MD PhD, Michael J. Thirman, MD, Andrew Artz, MD MS, Olatoyosi Odenike, MD, Hongtao Liu, MDPhD, Jane E. Churpek, MD, Darren King, MD, Elizabeth Rich, MD, Kwang Jin Choi, MD, Randall W. Knoebel, PharmD, BCOP, Wendy Stock, MD
Journal: Blood
Blood (2015) 126 (23): 2518.
https://doi.org/10.1182/blood.V126.23.2518.2518
Published: 2015
Journal Articles

Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)

Yasmin H Karimi, MD, Nitin Jain, MD, Margaret Green, Lucy A Godley, MD, PhD, Howie Lawrence Weiner, Gregory Malnassy, Noreen Fulton, Andrew Artz, MD MS, Hongtao Liu, MDPhD, Michael J. Thirman, MD, Michael Daunov, Richard A. Larson, MD, Wendy Stock, MD, Olatoyosi Odenike, MD
Journal: Blood
Blood (2015) 126 (23): 3777.
https://doi.org/10.1182/blood.V126.23.3777.3777
Published: 2015
Journal Articles

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Courtney DiNardo, MD, Daniel Pollyea, MD MS, Keith Pratz, MD, Michael J. Thirman, MD, Anthony Letai, MD PhD, Mark Frattini, MD PhD, Brian Jonas, MDPhD, Joel Leverson, PhD, Ming Zhu, PhD, Martin Dunbar, DrPH, Nancy Falotico, Rachel Kirby, BA, Suresh Agarwal, PhD, Mack Mabry, MD, Jalaja Potluri, MD, Rod A. Humerickhouse, MD PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2015) 126 (23): 327.
https://doi.org/10.1182/blood.V126.23.327.327
Published: 2015